I think it's quite fair to look on the job ad with a critical eye given the roles advertised pre-Sprinter results but would look to add
- if the company do indeed have a PT or a JV on the cards, the senior hires from 2021 would look to have been a very good investment
- all data from all trials should be unblinded and available to the company (even if they don't own it/aren't allowed to publish it re Activ2)
Dr Monk presenting:
Inhaled IFN-ß (SNG001) for the treatment of COVID-19 and other severe viral lung infections
https://www.intertek.com/pharmaceutical/events/inhaled-nasal-biologics-dna-forum/
A really interesting one. Published 2 days ago and authored by a host of researchers from Uni Southampton, Uni Liverpool and TopMD
"Conclusions: Gene expression signatures from blood taken at the point of admission to hospital predicted ICU admission of treatment naïve patients with COVID-19."
https://www.frontiersin.org/articles/10.3389/fimmu.2022.988685/full
More from Topol in this week's Time feature
"Dr. Eric Topol, founder of the Scripps Research Translational Institute and a prolific parser of COVID-19 research on Twitter, says the NIH is doing good research on the underlying science of Long COVID, but he’d like to see more trials focused on treatments. “You need to do both, because we can’t wait another year or two for the biology to be better defined,” Topol says. (The NIH says it will begin treatment-focused trials this fall. Mahon says the CDC also continues to research Long COVID symptoms, prevalence, and risk factors.)"
https://time.com/6213103/us-government-long-covid-response/
Titania if I recall correctly the median time from symptoms to first dose in sprinter was 8 days (unsure if it was the same in ITT Vs PP cohorts)
Also recall that the company stated the majority of patients that were disqualified from the PP cohort was based on "failure to receive at least 2 doses in the first 3 days of treatment"
Nice one HSD - I thought as much.
Think it's of interest that these results were achieved with a median treatment start of 8 days after symptom onset in hospitalised patients (as per sprinter cohort) curious how that would translate to early treatment as per ACTIV
"Professor Chris Brightling, NIHR Senior Investigator, Department of Respiratory Sciences at the University of Leicester, said: "This promising Long COVID data is very welcome in an area of enormous clinical need. While it merits further investigation, it is exciting to see that SNG001 may have a positive effect in reducing some of the most recognised and problematic symptoms associated with Long COVID which afflicts millions of people and for which there are no current treatments."
Genuine Q - has anyone - BP included - shown any efficacy vs long covid?